Compounds > acetylgalactosamine
Page last updated: 2024-08-23

acetylgalactosamine and Amyloid Neuropathy Type 1

acetylgalactosamine has been researched along with Amyloid Neuropathy Type 1 in 2 studies

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's2 (100.00)2.80

Authors

AuthorsStudies
Attarwala, H; Clausen, VA; Garg, P; Goel, V; Habtemariam, BA; Karsten, V; Melch, M; Robbie, GJ; Sweetser, MT; Vaishnaw, AK; Vest, J1
Holm, A; Kauppinen, S; Løvendorf, MB1

Reviews

1 review(s) available for acetylgalactosamine and Amyloid Neuropathy Type 1

ArticleYear
Development of siRNA Therapeutics for the Treatment of Liver Diseases.
    Methods in molecular biology (Clifton, N.J.), 2021, Volume: 2282

    Topics: Acetylgalactosamine; Amyloid Neuropathies, Familial; Animals; Gene Transfer Techniques; Humans; Liver Diseases; Porphyrias, Hepatic; Pyrrolidines; RNA Interference; RNA, Small Interfering; RNAi Therapeutics

2021

Trials

1 trial(s) available for acetylgalactosamine and Amyloid Neuropathy Type 1

ArticleYear
Single-Dose Pharmacokinetics and Pharmacodynamics of Transthyretin Targeting N-acetylgalactosamine-Small Interfering Ribonucleic Acid Conjugate, Vutrisiran, in Healthy Subjects.
    Clinical pharmacology and therapeutics, 2021, Volume: 109, Issue:2

    Topics: Acetylgalactosamine; Adult; Amyloid Neuropathies, Familial; Asian People; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Half-Life; Healthy Volunteers; Humans; Male; Prealbumin; RNA; Single-Blind Method

2021